Xenon Pharmaceuticals Inc Cash Flow Conversion Efficiency
Xenon Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Xenon Pharmaceuticals Inc (XENE) has a cash flow conversion efficiency ratio of -0.140x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.48 Million) by net assets ($581.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Xenon Pharmaceuticals Inc (2012–2025)
Cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025. This chart illustrates how Xenon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Xenon Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Xenon Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Xenon Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Xenon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenon Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Xenon Pharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Van Lanschot NV
AS:VLK
|
0.878x |
|
Bright Horizons Family Solutions Inc
NYSE:BFAM
|
0.101x |
|
Luxi Chemical Group Co Ltd
SHE:000830
|
0.041x |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
-0.168x |
|
Inter Parfums Inc
NASDAQ:IPAR
|
0.000x |
|
Jiangxi Jovo Energy Co. Ltd
SHG:605090
|
-0.003x |
|
Sany Heavy Equipment International Holdings Company Limited
F:YXS
|
0.017x |
|
Aperam SA
AS:APAM
|
0.042x |
Annual Cash Flow Conversion Efficiency for Xenon Pharmaceuticals Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Xenon Pharmaceuticals Inc from 2012 to 2025. Review free cash flow generation of Xenon Pharmaceuticals Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $581.76 Million | $-279.12 Million | -0.480x | -99.68% |
| 2024-12-31 | $754.90 Million | $-181.39 Million | -0.240x | -53.42% |
| 2023-12-31 | $927.92 Million | $-145.33 Million | -0.157x | -14.80% |
| 2022-12-31 | $721.50 Million | $-98.43 Million | -0.136x | -7.97% |
| 2021-12-31 | $550.03 Million | $-69.50 Million | -0.126x | +55.01% |
| 2020-12-31 | $171.35 Million | $-48.12 Million | -0.281x | -457.67% |
| 2019-12-31 | $91.98 Million | $-4.63 Million | -0.050x | +85.02% |
| 2018-12-31 | $103.30 Million | $-34.72 Million | -0.336x | +57.95% |
| 2017-12-31 | $35.93 Million | $-28.73 Million | -0.799x | -161.07% |
| 2016-12-31 | $63.90 Million | $-19.57 Million | -0.306x | -3.24% |
| 2015-12-31 | $61.03 Million | $-18.10 Million | -0.297x | -8215.27% |
| 2014-12-31 | $72.78 Million | $266.00K | 0.004x | +102.65% |
| 2013-12-31 | $24.12 Million | $-3.32 Million | -0.138x | -103.82% |
| 2012-12-31 | $12.62 Million | $45.57 Million | 3.610x | -- |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more